Skip to main content
. 2016 Jul 1;5(8):2161–2168. doi: 10.1002/cam4.792

Table 3.

Univariate analysis of risk factors related to level V lymph node metastases

Variables Level V metastases P‐value
Present, n (%) Absent, n (%)
Total 27 (12.3) 193 (87.7)
Gender
Male 6 (22.2) 45 (23.3) 0.900
Female 21 (77.8) 148 (76.7)
Age (years)
Mean ± SD 41.9 ± 15.5 40.9 ± 13.2 0.708a
≥45 9 (33.3) 73 (37.8) 0.651
<45 18 (66.7) 120 (62.2)
Size (mm)
Mean ± SD 29.2 ± 20.7 20.3 ± 11.6 0.021b
>10 26 (96.3) 144 (74.6) 0.012
≤10 1 (3.7) 49 (25.4)
Location of primary tumor
Superior lobe 15 (55.6) 96 (49.7) 0.571
Middle lobe 19 (70.4) 108 (56.0) 0.156
Inferior lobe 11 (40.7) 65 (33.7) 0.470
Capsular invasion 24 (88.9) 152 (78.8) 0.218
Extrathyroidal extension 17 (63.0) 82 (42.5) 0.045
Lymphocytic thyroiditis 4 (14.8) 44 (22.8) 0.347
Central lymph node metastases
Ipsilateral 24 (88.9) 149 (77.2) 0.165
Metastatic ratio ≥50% 21 (77.8) 107 (55.4) 0.028
Contralateral 17 (63.0) 70 (36.3) 0.008
Bilateral 15 (55.6) 67 (34.7) 0.036
Lateral lymph node metastases
Level II 16 (59.3) 85 (44.0) 0.137
Level III 20 (74.1) 118 (61.1) 0.193
Level IV 18 (66.7) 104 (53.9) 0.211
Level II + III 13 (48.1) 68 (35.2) 0.193
Level III + IV 15 (55.6) 72 (37.3) 0.069
Level II + III + IV 11 (40.7) 41 (21.2) 0.026
a

The Student's t‐test was adopted.

b

The Wilcoxon rank‐sum test was adopted.